Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.
Approval Alert | Subcutaneous Daratumumab Combo in Newly Diagnosed Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC
2
Bolstering The Referral Process for CAR T-Cell Therapy in Multiple Myeloma
3
Sirexatamab Regimen May Improve PFS, OS in DKK1-High Colorectal Cancer
4
ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes
5